Gilead Sciences (GILD) PT Raised to $120 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $172.82 +3.19%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
BMO Capital analyst Evan David Seigerman raised the price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $115.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Gilead Sciences (GILD) PT Raised to $175 at Bernstein SocGen Group
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- Gilead and Kite to present 23 abstracts at ASH 2026 meeting
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
